Related Experiment Video
Updated: Mar 29, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation
Abstract:
Identification of targetable oncogenic mutations in non-small cell lung cancer (NSCLC) has been a major advance in cancer treatment. Laboratory techniques to assess human epidermal growth factor receptor 2 (HER2) positivity in NSCLC include immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next generation sequencing (NGS) for HER2 gene mutations. These tests have a controversial prognostic and predictive value, with an emerging association between HER2 gene mutations and treatment response to HER2 targeted therapy. We present a case of a woman with metastatic lung adenocarcinoma with HER2 positivity assessed by IHC and FISH, as well as a high gene copy number noted on NGS. She was observed to have significant disease progression following standard first-line platinum doublet chemotherapy. She was started on dual HER2 blockade in the second-line setting, which yielded a great response in the liver with stable disease elsewhere. To our knowledge, this is the first report describing successful use of dual HER2 blockade in metastatic HER2 positive NSCLC. We also review common laboratory techniques for determining HER2 positivity in NSCLC and their clinical applications.
Insights
Dual HER2 blockade shows promise for patients with metastatic non-small cell lung cancer (NSCLC) who are HER2 positive. This case report details a successful treatment response in a patient previously progressing on chemotherapy.
Area of Science:
- Oncology
- Molecular Diagnostics
- Cancer Therapeutics
Background:
- Targetable oncogenic mutations are crucial in non-small cell lung cancer (NSCLC) treatment.
- Assessing human epidermal growth factor receptor 2 (HER2) positivity in NSCLC involves immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), and next-generation sequencing (NGS).
- The prognostic and predictive value of HER2 testing in NSCLC is debated, but HER2 mutations are increasingly linked to targeted therapy response.
Observation:
- A patient with metastatic lung adenocarcinoma presented with HER2 positivity confirmed by IHC, FISH, and high copy number via NGS.
- The patient experienced disease progression despite standard first-line platinum doublet chemotherapy.
- The patient received second-line dual HER2 blockade therapy.
Findings:
- Dual HER2 blockade resulted in a significant response in liver metastases and stable disease elsewhere.
- This represents the first reported successful use of dual HER2 blockade in metastatic HER2-positive NSCLC.
Implications:
- Dual HER2 blockade offers a potential new therapeutic strategy for HER2-positive NSCLC.
- Further research is warranted to explore the efficacy of HER2-targeted therapies in this patient population.
- Understanding laboratory techniques for HER2 assessment is critical for guiding treatment decisions in NSCLC.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle